Study: Statins Don't Decrease Ventilator-Associated Pneumonia Mortality

A group of cholesterol-lowering drugs, statins, are not an effective therapy for reducing ventilator-associated pneumonia mortality rates, according to an article in The Journal of the American Medical Association.

Researchers investigated the use of statins to decrease 28-day mortality among VAP patients. The therapy had initially shown promising results in other studies.

After measuring 28-day, 14-day, intensive care unit and hospital mortality rates between a VAP group receiving statins and a VAP group receiving a placebo, researchers concluded there were no statistically significant differences in survival, and statins were no more effective than a placebo in improving any of the measured mortality rates.

More Articles on Quality:

Blame Game Keeps Healthcare Workers Stuck in Hand Hygiene Compliance Slump

Preventing Needless Hospital Deaths: Q&A With Dr. Ira Williams, Author of "Find the Black Box"

Compounding Pharmacy Meningitis Outbreak Caused 61 Deaths, 749 Infections, Study Says

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars